Innate Pharma SA Q3 FY2026 earnings call

The management team highlighted several critical operational milestones and strategic advancements across their pipeline during the third quarter of 2026:

Lacutamab (SOBI Partnership)

• The strategic partnership with SOBI to license Lacutamab for T-cell lymphoma is now effective.
• The TELEMAP Phase 3 confirmatory study has been initiated, with first patient dosing expected in Q1 2027.
• The company plans to file for accelerated approval in CEASARE syndrome based on existing Phase 2 data, with SOBI holding global commercial rights upon such approval.

IPH4502 (Nectin-4 ADC)

• Phase 1 dose escalation enrollment is complete for this differentiated Nectin-4 antibody-drug conjugate targeting advanced solid tumors.
• Preliminary data shows objective responses in heavily pretreated patients with a favorable safety profile.
• Full Phase 1 data will be presented at the EORTC NCI AACR Symposium on November 18, 2026.

Monalizumab (AstraZeneca Partnership)

• The Pacific 9 Phase 3 study in non-small cell lung cancer (NSCLC) has completed enrollment of 1,051 patients.
• High-level data readout is now expected in the first half of 2027, reflecting the event-driven nature of the trial.
• The program is supported by three earlier Phase 2 studies (COAST, NEO-COAST, NEO-COAST2).

Preclinical ADC Pipeline

• Development continues on next-generation ADC candidates utilizing proprietary linker technology.
• Strategy focuses on dual-targeted bispecific ADCs, specific ADCs for low-expressing tumors, and dual payload ADCs to overcome resistance.

Leadership Change

• CFO Frederic Lombard announced his departure at the end of December 2026; a search for his successor has been initiated.

As a pure-play biotechnology company focused on clinical-stage drug development, Innate Pharma does not report traditional product segment revenue or profit margins. The financial performance is characterized by the receipt of strategic partnership payments and cash position maintenance rather than commercial sales. Key financial metrics include:

• Cash Position: $96.8 million as of September 30, 2026, providing an anticipated cash horizon through the end of Q1 2028.
• Strategic Partnership Revenue (Lacutamab/SOBI): Received a $75 million upfront payment upon effectiveness of the licensing agreement. Eligible for up to $40 million in near-term milestones and up to $465 million in future regulatory/commercial milestones.
• Strategic Partnership Revenue (Monalizumab/AstraZeneca): Received $450 million to date under the co-development agreement. Additional potential milestones total up to $825 million, plus double-digit royalties outside Europe and 50% profit sharing in Europe.

• Financial Runway: Management confirmed that the current cash position of $96.8 million supports operations through the end of Q1 2028.
• Lacutamab Milestones: No specific timeline guidance provided beyond the expectation of receiving the $75 million upfront payment (already received) and eligibility for up to $40 million in near-term milestones connected to CEASARE syndrome.
• Clinical Readouts:
  • IPH4502 Phase 1 data presentation scheduled for November 18, 2026.
  • TELEMAP Phase 3 first patient dosing expected in Q1 2027.
  • Monalizumab Pacific 9 top-line data expected in H1 2027.
• Regulatory Filings: Plan to file for accelerated approval for Lacutamab in CEASARE syndrome in H2 2027, with potential approval in H1 2028.

• Clinical Trial Delays: The delay in Pacific 9 readout was noted as event-driven, but management cautioned against drawing conclusions about treatment efficacy or control arm performance from timing shifts alone.
• Regulatory Uncertainty: Accelerated approval for Lacutamab depends on successful Phase 3 results in CEASARE syndrome; failure could impact the value proposition for SOBI and future milestone payments.
• Key Personnel Risk: The departure of the Chief Financial Officer creates a temporary leadership gap during the search for a successor.
• Pipeline Execution Risk: Success relies heavily on the differentiation and safety profile of IPH4502 compared to competitors like Enfortumab vedotin, and the ability to advance preclinical ADC candidates into clinical proof-of-concept.

Q: What are the expectations for the upcoming IPH4502 poster presentation regarding patient numbers and follow-up, and what is the view on the head-and-neck cancer opportunity given recent EGFR bispecific successes? / A: CEO Jonathan Dickinson clarified that the Phase 1 basket study enrolled 76 patients across over 10 tumor types, including urothelial, NSCLC, and head-and-neck cancers. He emphasized that while preliminary anti-tumor activity was observed post-PADSF in these areas, the dataset per individual tumor type is limited due to varying doses and small sample sizes. Consequently, specific conclusions for any single tumor type cannot yet be drawn, and detailed efficacy/safety profiling will be revealed only at the November 18 symposium. Marcus Jensen confirmed no additional details would be disclosed prior to the presentation.

Q: Regarding the delay in the Pacific 9 readout for Monalizumab, what implications might this have on the experimental versus control arm performance, and what are the next steps for IPH4502 after the INA meeting? / A: Management stated it is difficult to speculate on the cause of the delay, noting that slower event rates could indicate either superior experimental arm performance or a stronger-than-expected control arm. They stressed that the blinded, event-driven nature of the AstraZeneca-led study means the delay itself is not a signal of efficacy or lack thereof. For IPH4502, next steps will involve protocol-defined drug development actions, with further information released during the KOL event following the poster presentation on November 18.